恩替卡韦联合聚乙二醇干扰素抗乙肝病毒疗效观察

Clinical Effect of Entecavir Combined with Pegylated Interferons in Patients with Hepatitis B

目的:探讨恩替卡韦联合聚乙二醇干扰素抗乙肝病毒的疗效。方法:乙肝抗病毒治疗患者72例随机分为试验组和对照组,每组36例。试验组给予恩替卡韦联合聚乙二醇干扰素抗病毒治疗;对照组单独给予恩替卡韦治疗。分别比较治疗24,48周,以及停药后6个月时两组患者的HBe Ag转换率、HBe Ag阴转率、HBV-DNA阴转率、HBs Ag清除率、AST和ALT复常率等指标,以及治疗期间两组的药品不良反应。结果:治疗24周时,两组患者各项指标比较,差异均无统计学意义(P>0.05);治疗48周和停药6个月时,试验组患者各项指标均明显高于对照组(P<0.05)。两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:聚乙二醇干扰素联合恩替卡韦抗乙肝病毒治疗临床疗效明显优于单用恩替卡韦,且安全性较好,值得临床推广。

Objective： To investigate the clinical effect of entecavir combined with pegylated interferons in the patients with hepati- tis B. Methods： Totally 72 patients with hepatitis B were randomly divided into the experimental group and the control group with 36 ones in each. The patients in the experimental group were treated with entecavir combined with pegylated interferons, and those in the control group were treated with entecavir. The clinical indicators in the two groups were detected and compared after the 24-week, 48- week and 6- month treatment. The adverse drug reactions in the two groups were recorded and compared. Results： After the 24-week treatment, the differences in the clinical indicators between the groups were not statistically significant （P 〉 0.05 ）. After the 48-week and 6-month treatment, the clinical indicators in the experimental group were obviously higher than those in the control group, and the differences were statistically significant （P 〈 0.05 ）. The difference in the adverse drug reactions in the two groups was not statistically significant （ P 〉 0.05）. Conclusion ： Compared with entecavir, pegylated interferon combined with entecavir in the treatment of hepa- titis B shows better clinical effect and security, which is more worthy of clinical promotion.